Patents by Inventor Mark A. Winter

Mark A. Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6124311
    Abstract: The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 26, 2000
    Assignee: Eli Lilly and Company
    Inventors: Srinivasan Chandrasekhar, Anne H. Dantzig, Robert L. Shepard, James J. Starling, Mark A. Winter
  • Patent number: 6121292
    Abstract: The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 19, 2000
    Assignee: Eli Lilly and Company
    Inventors: Srinivasan Chandrasekhar, Anne H. Dantzig, Robert L. Shepard, James J. Starling, Mark A. Winter
  • Patent number: 5552545
    Abstract: 5-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treating susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Homer L. Pearce, Mark A. Winter
  • Patent number: 5321150
    Abstract: 5-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treating susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: June 14, 1994
    Assignee: Eli Lilly and Company
    Inventors: Homer L. Pearce, Mark A. Winter
  • Patent number: 5284656
    Abstract: Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in accordance with this invention results in significant elevation of the neutrophil levels that compares favorably with delivery by subcutaneous injection. G-CSF can be administered in this manner to medically treat neutropenia, as well as to combat or prevent infections.
    Type: Grant
    Filed: September 29, 1992
    Date of Patent: February 8, 1994
    Assignee: Amgen Inc.
    Inventors: Robert M. Platz, Mark A. Winters, Colin G. Pitt
  • Patent number: 5159079
    Abstract: 4-Deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acid derivatives are provided as agents useful for treatment susceptible neoplasms in mammals. Pharmaceutical formulations and intermediates are also provided.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: October 27, 1992
    Assignee: Eli Lilly and Company
    Inventors: Homer L. Pearce, Mark A. Winter
  • Patent number: 5004699
    Abstract: A method for detecting organisms such as fungi and yeast in a sample attached to a solid phase, by detecting the presence of chitin in using lectin or anti-chitin antibodies.
    Type: Grant
    Filed: October 24, 1989
    Date of Patent: April 2, 1991
    Assignee: SRI International
    Inventor: Mark A. Winters
  • Patent number: 4560695
    Abstract: This invention provides certain isoxazole and isothiazole derivatives, their pharmaceutical formulations, and their use in inhibiting aromatase and treating or preventing estrogen-dependent diseases in mammals.
    Type: Grant
    Filed: June 18, 1984
    Date of Patent: December 24, 1985
    Assignee: Eli Lilly and Company
    Inventors: Kenneth S. Hirsch, Charles D. Jones, Harold M. Taylor, Mark A. Winter